Quick Answer
Alaunos Therapeutics, Inc. reported Diluted EPS of $2.20 per share (loss) for fiscal year 2025.
Alaunos Therapeutics, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$2.20 | +24.7% |
| 2024 | -$2.92 | +86.7% |
| 2023 | -$21.97 | -741.8% |
| 2022 | -$2.61 | -605.4% |
| 2021 | -$0.37 | +2.6% |
| 2020 | -$0.38 | +45.7% |
| 2019 | -$0.70 | -172.9% |
| 2018 | $0.96 | +281.1% |
| 2017 | -$0.53 | +59.8% |
| 2016 | -$1.32 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.55 | +21.4% | +12.7% |
| June 30, 2025 | -$0.63 | +11.3% | +6.0% |
| March 31, 2025 | -$0.67 | +36.2% | +4.3% |
| September 30, 2024 | -$0.70 | +86.8% | +1.4% |
| June 30, 2024 | -$0.71 | +87.1% | +32.4% |
| March 31, 2024 | -$1.05 | -66.7% | +80.2% |
| September 30, 2023 | -$5.30 | -13150.0% | +3.5% |
| June 30, 2023 | -$5.49 | -10880.0% | -771.4% |
- Alaunos Therapeutics, Inc. showed an increase of +24.7% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, Alaunos Therapeutics, Inc.’s diluted eps has declined by 66.7% (from $1.32 per share (loss) to $2.20 per share (loss)).
- The most recent figure is from Alaunos Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 31, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: